Sun Pharmaceutical Industries
Sun Pharmaceutical Industries
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return104%
-
Sales Growth36%
-
Return on Equity19 %
Why Super 50
New products, patents, acquisitions, focus on exiting low-margin businesses and rationalising operations by selling non-strategic plants is Sun Pharmaceutical Industries' secret sauce for growth and success. It is currently betting big on Tildrakizumab, an experimental psoriasis drug which recently completed last-stage trials and whose verdict will be out soon. It is India's largest and world's fifth-biggest drug maker.
